abstract：INTRODUCTION:Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS:Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason <...

journal_title：Prostate cancer and prostatic diseases

authors： Shah TT,Reddy D,Peters M,Ball D,Kim NH,Gomez EG,Miah S,Evans DE,Guillaumier S,van Rossum PSN,Van Son MJ,Hosking-Jervis F,Dudderidge T,Hindley R,Emara A,McCracken S,Greene D,Nigam R,McCartan N,Valerio M,Minhas S,

更新日期：2021-01-28 00:00:00

abstract：OBJECTIVES:To assess the efficacy of high-intensity interval training (HIIT) for improving cardiorespiratory fitness (CRF) in patients awaiting resection for urological malignancy within four weeks. SUBJECTS/PATIENTS AND METHODS:A randomised control trial of consecutive patients aged (>65 years) scheduled for major ur...

journal_title：Prostate cancer and prostatic diseases

authors： Blackwell JEM,Doleman B,Boereboom CL,Morton A,Williams S,Atherton P,Smith K,Williams JP,Phillips BE,Lund JN

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

journal_title：Prostate cancer and prostatic diseases

authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

journal_title：Prostate cancer and prostatic diseases

authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...

journal_title：Prostate cancer and prostatic diseases

authors： Duivenvoorden WCM,Naeim M,Hopmans SN,Yousef S,Werstuck GH,Dason S,Pinthus JH

更新日期：2020-09-28 00:00:00

abstract：BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

journal_title：Prostate cancer and prostatic diseases

authors： McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

更新日期：2020-09-03 00:00:00

abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

journal_title：Prostate cancer and prostatic diseases

authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Increasing evidence indicates an association between statins and reduced prostate cancer-specific mortality (PCSM). However, significant bias may exist in these studies. One particularly challenging bias to assess is the healthy user effect, which may be quantified by screening patterns. We aimed to evaluate...

journal_title：Prostate cancer and prostatic diseases

authors： Kumar A,Riviere P,Luterstein E,Nalawade V,Vitzthum L,Sarkar RR,Bryant AK,Einck JP,Mundt AJ,Murphy JD,Rose BS

更新日期：2020-09-01 00:00:00

abstract：:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...

journal_title：Prostate cancer and prostatic diseases

authors： Obek C,Doganca T,Argun OB,Kural AR

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...

journal_title：Prostate cancer and prostatic diseases

authors： Meziou S,Ringuette Goulet C,Hovington H,Lefebvre V,Lavallée É,Bergeron M,Brisson H,Champagne A,Neveu B,Lacombe D,Beauregard JM,Buteau FA,Riopel J,Pouliot F

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Growing evidence suggests that men exposed to androgen deprivation therapy (ADT) have an increased risk of cardiovascular disease. While exercise has shown to attenuate some adverse effects of ADT, the effects on cardiometabolic health have not been systematically evaluated. OBJECTIVE:To evaluate the effect...

journal_title：Prostate cancer and prostatic diseases

authors： Bigaran A,Zopf E,Gardner J,La Gerche A,Murphy DG,Howden EJ,Baker MK,Cormie P

更新日期：2020-08-28 00:00:00

abstract：BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

journal_title：Prostate cancer and prostatic diseases

authors： Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

更新日期：2020-07-31 00:00:00

abstract：BACKGROUND:Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the cost-effectiveness of these treatment options has not been fu...

journal_title：Prostate cancer and prostatic diseases

authors： Chiang CL,So TH,Lam TC,Choi HCW

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...

journal_title：Prostate cancer and prostatic diseases

authors： Matsumoto K,Akita H,Narita K,Hashiguchi A,Takamatsu K,Takeda T,Kosaka T,Mizuno R,Kikuchi E,Oya M,Jinzaki M

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, progno...

journal_title：Prostate cancer and prostatic diseases

authors： Eskra JN,Rabizadeh D,Pavlovich CP,Catalona WJ,Luo J

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

journal_title：Prostate cancer and prostatic diseases

authors： Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT. METH...

journal_title：Prostate cancer and prostatic diseases

authors： Schmidt B,Eapen RS,Cowan JE,Broering JM,Greene KL,Carroll PR,Cooperberg MR

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...

journal_title：Prostate cancer and prostatic diseases

authors： Crombag MBS,van Nuland M,Bergman AM,Rosing H,Schellens JHM,Huitema ADR,Beijnen JH

更新日期：2019-03-01 00:00:00

abstract：INTRODUCTION:Recent technological advancements and the introduction of modern anatomical and functional sequences have led to a growing role for multiparametric magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of early prostate cancer. This includes men who have been diagnosed with lo...

journal_title：Prostate cancer and prostatic diseases

authors： Stavrinides V,Giganti F,Emberton M,Moore CM

更新日期：2019-03-01 00:00:00

abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

journal_title：Prostate cancer and prostatic diseases

authors： Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients ...

journal_title：Prostate cancer and prostatic diseases

authors： Miller K,Steger GG,Niepel D,Lüftner D

更新日期：2018-11-01 00:00:00

abstract：OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

journal_title：Prostate cancer and prostatic diseases

authors： Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. METHODS:In this analysis, we...

journal_title：Prostate cancer and prostatic diseases

authors： McKay RR,Montgomery B,Xie W,Zhang Z,Bubley GJ,Lin DW,Preston MA,Trinh QD,Chang P,Wagner AA,Mostaghel EA,Kantoff PW,Nelson PS,Kibel AS,Taplin ME

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...

journal_title：Prostate cancer and prostatic diseases

authors： Porter CM,Shrestha E,Peiffer LB,Sfanos KS

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and c...

journal_title：Prostate cancer and prostatic diseases

authors： Werneburg GT,Kongnyuy M,Halpern DM,Salcedo JM,Kosinski KE,Haas JA,Schiff JT,Corcoran AT,Katz AE

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...

journal_title：Prostate cancer and prostatic diseases

authors： Jamnagerwalla J,Howard LE,Allott EH,Vidal AC,Moreira DM,Castro-Santamaria R,Andriole GL,Freeman MR,Freedland SJ

更新日期：2018-06-01 00:00:00

abstract：:This corrects the article DOI: 10.1038/pcan.2017.5. ...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there i...

journal_title：Prostate cancer and prostatic diseases

authors： Tosco L,Laenen A,Briganti A,Gontero P,Karnes RJ,Albersen M,Bastian PJ,Chlosta P,Claessens F,Chun FK,Everaerts W,Gratzke C,Graefen M,Kneitz B,Marchioro G,Salas RS,Tombal B,Van den Broeck T,Moris L,Battaglia A,van d

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METH...

journal_title：Prostate cancer and prostatic diseases

authors： Paller CJ,Pantuck A,Carducci MA

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS:Using the National Cancer Data Base for 2...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...

journal_title：Prostate cancer and prostatic diseases

authors： Gökce MI,Sundi D,Schaeffer E,Pettaway C

更新日期：2017-06-01 00:00:00

abstract：BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...

journal_title：Prostate cancer and prostatic diseases

authors： Narang AK,Trieu J,Radwan N,Ram A,Robertson SP,He P,Gergis C,Griffith E,Singh H,DeWeese TA,Honig S,Annadanam A,Greco S,DeVille C,McNutt T,DeWeese TL,Song DY,Tran PT

更新日期：2017-06-01 00:00:00

abstract：BACKGROUND:Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with int...

journal_title：Prostate cancer and prostatic diseases

authors： Dall'Era MA,Klotz L

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the progno...

journal_title：Prostate cancer and prostatic diseases

authors： Jang WS,Yoon CY,Kim MS,Kang DH,Kang YJ,Jeong WS,Abalajon MJ,Ham WS,Choi YD

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...

journal_title：Prostate cancer and prostatic diseases

authors： Zhao Y,Lv JJ,Chen J,Jin XB,Wang MW,Su ZH,Wang LY,Zhang HY

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other ...

journal_title：Prostate cancer and prostatic diseases

authors： Wadhwa H,Terris MK,Aronson WJ,Kane CJ,Amling CL,Cooperberg MR,Freedland SJ,Abern MR

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...

journal_title：Prostate cancer and prostatic diseases

authors： Mano R,Eastham J,Yossepowitch O

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...

journal_title：Prostate cancer and prostatic diseases

authors： Den RB,Santiago-Jimenez M,Alter J,Schliekelman M,Wagner JR,Renzulli Ii JF,Lee DI,Brito CG,Monahan K,Gburek B,Kella N,Vallabhan G,Abdollah F,Trabulsi EJ,Lallas CD,Gomella LG,Woodlief TL,Haddad Z,Lam LL,Deheshi S,Wa

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

journal_title：Prostate cancer and prostatic diseases

authors： Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

journal_title：Prostate cancer and prostatic diseases

authors： van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

更新日期：2016-03-01 00:00:00